Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
BRISBANE, Calif., March 27, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that it has been named an M&A Advisor Turnaround Award winner for Chapter 11 Reorganization of the Year.
KaloBios received the award in the $10 million to $25 million company size category for its work to successfully emerge from Chapter 11 bankruptcy on June 30, 2016.
“This award highlights our ability to execute in challenging circumstances to reach our goals and ultimately transform KaloBios,” said Cameron Durrant, MD, KaloBios chairman and CEO. “We are grateful for the recognition of our very talented team’s efforts.”
The award was presented at M&A Advisor’s 11th Annual Distressed Investing Summit. For more information on the conference and the award, please visit: http://www.cvent.com/events/2017-distressed-investing-summit-featuring-11th-annual-turnaround-awards/event-summary-4a15eb768f714edd8170809430c0a745.aspx.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
